DEVELOPMENT OF BISPECIFIC ANTIBODY MIMETICS MATTHEW ...

Tebotelimab. 6. 1514. H-L Roche. RO7247669. 3. 538. B.I.. BI754111. 5. 649 ... a) Conducted by CYTLIMIC in Japan; b) Conducted by EOC in China.

Autres Cours:

Form 10-K for Macrogenics INC filed 03/15/2023 - Annual Reports

The global leader in developing LAG-3 therapeutics - Immutep

Immune checkpoint inhibitors and SARS-CoV2 infection

no28.pdf - ??????

?????????????2018 ????? - ???????

'24 ? 7 ? ????????? ????

? ? ? ? ? - ???????? ????????

???? - ???

???????? Vol. 26 No. 2 2011

?????????

?????????????? ?? 54 ??????????

???????? U-ENG23 22051 LJ55 - ????? - ????